Key facts
- This page summarizes Gary A. Lyons's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Oct 2024, 19:15.
Gary A. Lyons - 04 Oct 2024 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- Director
- Issuer ticker
- TVTX
- Reported as of
- 04 Oct 2024
- Net transaction value
- -$169,901
- SEC form
- 4
- Accepted by SEC
- 04 Oct 2024, 19:15:51 UTC
- Prior SEC filing
- 15 Aug 2024
- Next SEC filing
- 16 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gary A. Lyons filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 04 Oct 2024.
Change
- Previous filing in this sequence was filed on 15 Aug 2024.
- Current net transaction value: -$169,901.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Options Exercise
- Transaction value
- $419,200
- Shares
- +40,000
- Change %
- +78%
- Price
- $10.48
- Shares after
- 91,000
- Date
- 04 Oct 2024
- Ownership
- Direct
TVTX
transaction
Common Stock
Sale
- Transaction value
- $303,874
- Shares
- -21,179
- Change %
- -23%
- Price
- $14.35
- Shares after
- 69,821
- Date
- 04 Oct 2024
- Ownership
- Direct
- Footnotes
- F1, F2
TVTX
transaction
Common Stock
Sale
- Transaction value
- $285,227
- Shares
- -18,821
- Change %
- -27%
- Price
- $15.15
- Shares after
- 51,000
- Date
- 04 Oct 2024
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TVTX
transaction
Derivative
Stock option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 0
- Date
- 04 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,000
- Exercise price
- $10.48
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
This sale was made pursuant to a written plan adopted on March 16, 2023 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person on October 8, 2014 with an expiration date of October 8, 2024.
Footnote F2
The weighted average sale price for the transaction reported was $14.3479, and the range of prices were between $13.92 and $14.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Footnote F3
The weighted average sale price for the transaction reported was $15.1547, and the range of prices were between $14.92 and $15.44. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Footnote F4
The stock option is fully vested and exercisable.